U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2023
455
Name Type Language
Elranatamab
INN   USAN  
Official Name English
elranatamab [INN]
Common Name English
ANTI-CD3/ANTI-BCMA BISPECIFIC MONOCLONAL ANTIBODY PF-06863135
Common Name English
RN613
Code English
ELRANATAMAB [USAN]
Common Name English
RN-613
Code English
PF-06863135
Code English
Elranatamab [WHO-DD]
Common Name English
Immunoglobulin G2-kappa, anti-(Homo sapiens T-cell surface glycoprotein CD3 epsilon chain CD3E (T-cell surface antigen T3/Leu-4 epsilon chain)), human-Mus musculus monoclonal disulfide with immunoglobulin G2-kappa, anti-(Homo sapiens - Tumor necrosis fac
Common Name English
Immunoglobulin G2 [224-arginine,265-alanine,330-serine,331-serine], anti-(human CD3 antigen ε-chain) (human-Mus musculus monoclonal PF-06863059 γ2-chain), disulfide with human-Mus musculus monoclonal PF-06863059 κ-chain, (223→217′)(227→221′)(2
Common Name English
B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 840721
Created by admin on Sat Dec 16 13:33:43 UTC 2023 , Edited by admin on Sat Dec 16 13:33:43 UTC 2023
Code System Code Type Description
USAN
HI-199
Created by admin on Sat Dec 16 13:33:43 UTC 2023 , Edited by admin on Sat Dec 16 13:33:43 UTC 2023
PRIMARY
FDA UNII
L0HR9A577V
Created by admin on Sat Dec 16 13:33:43 UTC 2023 , Edited by admin on Sat Dec 16 13:33:43 UTC 2023
PRIMARY
CAS
2408850-14-4
Created by admin on Sat Dec 16 13:33:43 UTC 2023 , Edited by admin on Sat Dec 16 13:33:43 UTC 2023
PRIMARY
NCI_THESAURUS
C146860
Created by admin on Sat Dec 16 13:33:43 UTC 2023 , Edited by admin on Sat Dec 16 13:33:43 UTC 2023
PRIMARY
INN
11838
Created by admin on Sat Dec 16 13:33:43 UTC 2023 , Edited by admin on Sat Dec 16 13:33:43 UTC 2023
PRIMARY
DRUG BANK
DB15395
Created by admin on Sat Dec 16 13:33:43 UTC 2023 , Edited by admin on Sat Dec 16 13:33:43 UTC 2023
PRIMARY
ACTIVE MOIETY
Elranatamab
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966